These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

186 related articles for article (PubMed ID: 11050782)

  • 1. The primary prevention of coronary heart disease with statins: practice headache or public health?
    Evans PH
    Br J Gen Pract; 2000 Sep; 50(458):695-7. PubMed ID: 11050782
    [No Abstract]   [Full Text] [Related]  

  • 2. Statins and the prevention of coronary heart disease: striking a balance that is desirable, affordable, and achievable.
    Ritchie LD
    Br J Gen Pract; 2000 Sep; 50(458):693-5. PubMed ID: 11050781
    [No Abstract]   [Full Text] [Related]  

  • 3. [Guideline for management of lipid metabolism].
    Ishibashi S
    Nihon Rinsho; 2002 Sep; 60 Suppl 9():675-8. PubMed ID: 12387068
    [No Abstract]   [Full Text] [Related]  

  • 4. Gauging the impact of statins using number needed to treat.
    Kumana CR; Cheung BM; Lauder IJ
    JAMA; 1999 Nov; 282(20):1899-901. PubMed ID: 10580441
    [No Abstract]   [Full Text] [Related]  

  • 5. The new National Cholesterol Education Program guidelines: clinical challenges for more widespread therapy of lipids to treat and prevent coronary heart disease.
    Eidelman RS; Lamas GA; Hennekens CH
    Arch Intern Med; 2002 Oct; 162(18):2033-6. PubMed ID: 12374510
    [No Abstract]   [Full Text] [Related]  

  • 6. Statins and risk of coronary heart disease.
    Ebrahim S; Smith GD
    JAMA; 2000 Jun; 283(22):2935-6. PubMed ID: 10865267
    [No Abstract]   [Full Text] [Related]  

  • 7. Statins and risk of coronary heart disease.
    Clemenson ND
    JAMA; 2000 Jun; 283(22):2935; author reply 2936. PubMed ID: 10865266
    [No Abstract]   [Full Text] [Related]  

  • 8. Implication of recent trials with b-hydroxy-b-methylglutaryl coenzyme A reductase inhibitors for hypertension management.
    Haq IU; Wallis EJ; Jackson PR; Yeo WW; Ramsay LE
    J Hypertens; 1999 Nov; 17(11):1641-6. PubMed ID: 10608479
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Statins (HMG-CoA reductase inhibitors)].
    Gotoda T
    Nihon Rinsho; 2006 Nov; 64(11):2113-8. PubMed ID: 17087305
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Switching to statins: a challenge for primary care.
    Fisher NG; Marshall AJ; Went J
    J R Soc Med; 1999 Oct; 92(10):522-4. PubMed ID: 10692904
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [ALLHAT [Antihypertensive and Lipid Lowering Treatment to Prevent Heart Attack Trial]].
    Tomiyama H; Doba N
    Nihon Rinsho; 2001 Mar; 59 Suppl 3():393-7. PubMed ID: 11347101
    [No Abstract]   [Full Text] [Related]  

  • 12. Cost-effectiveness analysis of lipid-modifying therapy in Canada: comparison of HMG-CoA reductase inhibitors in the primary prevention of coronary heart disease.
    Jolain B; Pettitt D
    Clin Ther; 1995; 17(3):572-80. PubMed ID: 7585861
    [No Abstract]   [Full Text] [Related]  

  • 13. Primary prevention of coronary heart disease: where do we go from here?
    Gotto AM
    Arch Intern Med; 2001 Apr; 161(7):922-4. PubMed ID: 11295953
    [No Abstract]   [Full Text] [Related]  

  • 14. An evidence-based assessment of the NCEP Adult Treatment Panel II guidelines. National Cholesterol Education Program.
    Ansell BJ; Watson KE; Fogelman AM
    JAMA; 1999 Dec; 282(21):2051-7. PubMed ID: 10591388
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Treatment of high blood cholesterol in patients with coronary heart disease].
    Nagai Y; Yamashita S
    Nihon Rinsho; 2003 Apr; 61 Suppl 4():675-81. PubMed ID: 12735049
    [No Abstract]   [Full Text] [Related]  

  • 16. Statin therapy in older persons: pertinent issues.
    Grundy SM
    Arch Intern Med; 2002 Jun; 162(12):1329-31. PubMed ID: 12076230
    [No Abstract]   [Full Text] [Related]  

  • 17. Improving health outcomes without increasing costs: maximizing the full potential of lipid reduction therapy in the primary and secondary prevention of coronary heart disease.
    Jacobson TA
    Curr Opin Lipidol; 1997 Dec; 8(6):369-74. PubMed ID: 9412778
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Status of secondary prevention in patients undergoing coronary revascularization.
    Allen JK; Blumenthal RS; Margolis S; Young DR
    Am J Cardiol; 2001 May; 87(10):1203-6: A7. PubMed ID: 11356400
    [No Abstract]   [Full Text] [Related]  

  • 19. Cost-effectiveness of statins.
    Reckless JP
    Curr Opin Lipidol; 2000 Aug; 11(4):351-6. PubMed ID: 10945715
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Therapy with hydroxymethylglutaryl coenzyme a reductase inhibitors (statins) and associated risk of incident cardiovascular events in older adults: evidence from the Cardiovascular Health Study.
    Lemaitre RN; Psaty BM; Heckbert SR; Kronmal RA; Newman AB; Burke GL
    Arch Intern Med; 2002 Jun; 162(12):1395-400. PubMed ID: 12076239
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.